Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 41Neoplasms, Plasma Cell 16Lymphoma, Non-Hodgkin 13Lymphoma 13Leukemia, Myeloid, Acute 13Leukemia 13Myelodysplastic Syndromes 11Hodgkin Disease 10Lymphoma, Mantle-Cell 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, Follicular 7Leukemia, Lymphocytic, Chronic, B-Cell 6Lymphoma, Large B-Cell, Diffuse 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Congenital Abnormalities 4Neuroblastoma 3Melanoma 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Myeloid, Accelerated Phase 3Leukemia, Biphenotypic, Acute 3Hematologic Neoplasms 3Graft vs Host Disease 3Burkitt Lymphoma 3Smoldering Multiple Myeloma 2Neoplasms 2Myeloproliferative Disorders 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, B-Cell 2Leukemia, Myelomonocytic, Juvenile 2

Interventions

liposomal doxorubicin 1Melphalan 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Patient Participation × Melphalan × Clear all
NCT00985907 2020-06-17

DMV

University of California, San Francisco

Phase 1/2 Terminated
13 enrolled 8 charts
Plasma cell

Multiple Myeloma, Patient Participation, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡